Tracer library / [169Er]Er-PSMA-617

Structure of PSMA-617 (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 122706786

[169Er]Er-PSMA-617

Also written as PSMA-617; Pluvicto

Radionuclide: Er-169 t½ 13536 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 0

Preclinical only, no clinical indication yet

What it is

Compound class: PSMA-617, a urea-based PSMA-targeting small molecule (radiolabeled with Er-169)
Target / mechanism: —
Clinical application: Metastasized cancer diseases (potential receptor-targeted radionuclide therapy) PMID 33968955
Theranostic pair: [111In]In-PSMA-617

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [169Er]Er-PSMA-617, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68, In-111. Stage set/updated at stage 39 from PMID 33968955: 'The quality of the 169Er product permitted radiolabeling and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a 169Er-PSMA-617, to show the potential of 169Er to reduce tumor cell viability.'.